PrEP UptakePOWER UpNCT05626452
PrEP Optimization Among Women to Enhance Retention and Uptake
A study testing PrEP Education, Provider training and EMR Optimization in people with PrEP Uptake, run by University of Chicago at 1 site in United States.
Trial summary
Black women experience one of the highest incidences of HIV among all subpopulations in the United States, but pre-exposure prophylaxis (PrEP) use among Black cisgender women is very limited. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- PrEP Uptake
- What is being tested?
- PrEP Education, Provider training and EMR Optimization
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 724 participants
- Where
- 1 siteUnited States
- Study dates
- 10 Aug 2023to 30 Apr 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age 18 years or older
- HIV-negative
Who cannot join
- Younger than age 18 years
- HIV-positive
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Implementation and Dissemination of Evidence-Based Interventions to Improve PrEP Care Continuum Outcomes Among Women in Community Health Clinics in the Southern U.S.
Black women experience one of the highest incidences of HIV among all subpopulations in the United States, but pre-exposure prophylaxis (PrEP) use among Black cisgender women is very limited. The investigators will implement four strategies (provider training, patient education, EMR optimization, and PrEP navigation) at 12 community health clinics in the Midwest and South. The investigators predict that PrEP use and other related outcomes will improve for participants after the intervention period.
Read the detailed description
Research Design After the investigators have adapted the POWER-Up strategies for use in the new setting, the investigators will conduct a hybrid type II trial within the framework of a cluster randomized, cross-sectional stepped wedge study. The investigators will use the RE-AIM framework for evaluation. The investigators will utilize a cluster randomized, cross-sectional stepped wedge trial, including sites in the South and the Midwest. This study design will allow us to roll out the intervention across diverse geographic areas and assess the change in clinical and implementation outcomes from the pre-intervention (control) and the post intervention (intervention) periods. The cluster, or unit of analysis, is each CHC, N=12 (8 in the South, 4 in the Midwest). In a stepped wedge study, each cluster contributes both time and observations to the control condition (usual care) and the intervention condition (strategies to increase PrEP use). Every cluster switches from the control to the intervention at regular time intervals ("steps"), but at different points in calendar time. More than one cluster may start the intervention at a step, but the step at which a cluster switches from control to intervention is randomized. The design is cross-sectional as outcomes are obtained from the subset of patients seen during each time period at each clinic rather than following individually recruited patients over time. This use of clinics under both intervention and control conditions improves precision when intra-cluster correlation is high, which is likely among the CHCs the investigators have chosen.
In our stepped wedge design, each step is 6 months long, and there are 4 waves of intervention implementation (three sites begin the intervention at the same step, a mix from the South and the Midwest, N=12). Three CHC sites will be randomized to each step occurring at 6-month intervals. Each cluster also undergoes a 6-month transition period when the individual clinics will prepare to implement the intervention package.
Although the investigators hypothesize that the effect of this intervention will increase PrEP uptake among participants, the investigators powered this study to ensure that the investigators could detect a range of intervention effectiveness. The investigators used the R statistical package swCRTdesign V3.1 to verify that a sample of 50 participants at 6 different times ("steps") each lasting 6 months, at the 12 CHC sites ("clusters") provides adequate power (>80%) to detect a change from a baseline of 1% of eligible participants receiving prescriptions for PrEP to 2% with an ICC of 0.2 and a CAC of 0.80.60. This minimum sample size per time interval is one that can easily be met by all of the clinics used as sites in this study (100 eligible participants per calendar year).
A key element of the research infrastructure will be AllianceChicago's uniform EMR system, which is distinguished by the integration of evidence-based practice recommendations into the end user interface to provide clinical decision support at the point of care. AllianceChicago's information technology (IT) team will create a study specific fields to measure study outcomes. The IT team will build custom reports in their data warehouse to access and validate in real-time. Reports will be built to pull data (ICD, CPT/HCPCS, and RXNORM codes, laboratory results, demographic characteristics) from the medical record and billing claims, and will be used to determine implementation success for the RE-AIM outcomes of effectiveness and maintenance. The investigators will utilize the Health Catalyst Tool which already has reports built to monitor PrEP care continuum outcomes. Additional reports will be built to monitor: 1) Participants who receive HIV risk assessment 2) participants who receive PrEP education; 3) participants who receive PrEP navigation; 4) PrEP prescriptions among eligible participants.
Implementation Patient education: CHC staff will perform HIV risk assessment for participants who present at the CHCs for care. HIV risk assessment will consist of asking questions regarding PrEP indications adapted from the USHS guidelines for PrEP (e.g., sexual partners, recent STIs, condom use, drug use, etc). For participants who meet criteria of "PrEP eligibility," patient education regarding PrEP will be provided. Patient education occurs at each clinic visit.
Provider training: Providers will complete 3 sessions of 1-hour virtual trainings regarding PrEP (providing patient education, identifying PrEP-eligible participants, offering PrEP, etc.). CHCs will provide protected time for providers to complete the trainings. Trainings will be virtual but also interactive, including the opportunities for providers to use electronic avatars to practice difficult conversations with virtual participants. Monthly audit and feedback will be provided post-training to measure and support sustained behavior change. The investigators will integrate PrEP outcomes reports into the overall quality metric reporting for each clinic. Every month the medical director of each clinic reviews quality metrics for the clinical site. The medical director reports the metrics during monthly clinic meetings and steps are taken to address any metrics that fall short of the expected benchmark. Data on clinic staff's use of PrEP clinical decision support tools and PrEP care continuum outcomes will be incorporated into standard monthly quality report. During monthly site check-ins, the investigators will review this data with the medical director and clinical champions.
EMR optimization: AllianceChicago will incorporate PrEP clinical decision support, including PrEP indication documentation, PrEP order set, and electronic notifications of PrEP-eligible participants into the CHC's EMR and provide weekly reports of PrEP care continuum outcomes for the CHC to review and act upon.
PrEP navigation: The investigators will work with the CHCs to engage staff in the adapted PrEP support roles using manualized procedures and training. PrEP navigators will meet with participants 2-3 times initially to support PrEP uptake, and will check in with patients monthly thereafter (appointment, refill reminders will be based on participants' own schedules).
Monitoring and Process Evaluation with Feedback: The investigators will track the implementation process and provide feedback and support to the CHC for challenges in implementing the strategies, as well as ongoing feedback on interim outcomes including number of participants who underwent HIV risk assessment, the number who discussed PrEP with a provider, proportion initiating PrEP, and results of provider training. Results will be discussed between the research team and each CHC to understand barriers and identify and document adaptations needed using Stirman's FRAME methodology. Broadly, the investigators will discuss and document (1) what and why the investigators adapted, (2) goals of the adaptation, (3) who was involved in the adaptation process, (4) when the investigators adapted, (5) forms of adaptation, and (6) measurement and evaluation.
Evaluation: Utilizing the RE-AIM framework, the investigators will evaluate the success of the implementation strategies. The investigators will gather feedback from CHC providers, staff, and participants using mixed methods with both quantitative surveys and qualitative interviews. For evaluation of the provider training, The investigators will use the Kirkpatrick four-level training evaluation model. The investigators will use provider-level quantitative surveys to assess the four-levels of training: satisfaction and perceived value (Level 1); knowledge and self-efficacy (Level 2); application of knowledge (Level 3; i.e., number of participants offered PrEP); and effectiveness (Level 4; i.e., the increase in proportion of participants on PrEP). Data regarding number of participants who had PrEP education, discussions, and who initiated and persisted on PrEP will be collected from the EMR with electronic reports developed by AllianceChicago. To assess provider and CHC staff feedback about the implementation strategies, the investigators will use surveys to assess the following measures: Acceptability of Intervention Measure (AIM)), appropriateness (Intervention Appropriateness Measure (IAM)), and feasibility (Feasibility of Intervention Measure (FIM)). In addition, the investigators will recruit 400 participants to complete surveys regarding acceptability (AIM) of the POWER Up strategies.
- Conditions
- PrEP Uptake
- Being tested
- PrEP Education, Provider training, EMR Optimization, PrEP Navigation, Provider Audit and Feedback
- Keywords
- Pre-exposure prophylaxis, Stepped-wedge randomized trial
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PrEP EducationBehavioural
Education for participants regarding PrEP
Provider trainingBehavioural
Training for medical providers at CHCs about how to identify participants eligible for PrEP, how to perform behavioral risk assessment and discussion of PrEP, and how to prescribe PrEP and monitor PrEP
EMR OptimizationOther
EMR modifications to enhance PrEP care continuum outcomes including HIV risk assessment, identification of participants eligible for PrEP, provision of PrEP education, clinical decision support tools for prescription of PrEP, and tracking of PrEP care continuum outcomes using an electronic population health management tool
PrEP NavigationOther
Use of CHC staff members to assist participants with obtaining PrEP and attending PrEP care appointments
Provider Audit and FeedbackOther
Audit of provider rates of PrEP prescription and persistence among participants and regular provision of feedback to providers with their performance on these PrEP measures
| Study group | Role | What they receive |
|---|---|---|
| Usual Care | No intervention | The current mechanisms used at each healthcare site to assess HIV risk/ take a sexual history, assess PrEP eligibility, identify PrEP ineligibility for otherwise PrEP eligible patients, provide PrEP education, offer PrEP, provide PrEP navigation, measure PrEP uptake, and measure PrEP persistence/retention. |
| Intervention | Experimental | Implementation of 1) Patient Education, 2) Provider PrEP training, 3) EMR optimization, and 4) PrEP navigation, and the effect of these intervention components on the ability of each site to assess HIV risk/take a sexual history, assess PrEP eligibility, identify PrEP ineligibility for otherwise PrEP-eligible patients, provide PrEP education, offer PrEP, provide PrEP navigation, measure PrEP uptake, and measure PrEP persistence/retention. Receives: Behavioral: PrEP Education; Behavioral: Provider training; Other: EMR Optimization; Other: PrEP Navigation; Other: Provider Audit and Feedback |
What is being measured
The primary outcome is the main question the study is designed to answer.
PrEP uptake
Number of participants initiating PrEP
Measured: Baseline through 36 months
Secondary outcomes (21)
PrEP persistence consecutive months
Number of participants with six consecutive months of PrEP prescriptions
Measured: Baseline through 36 months
PrEP persistence amount of coverage
Number of participants who achieve appropriate coverage of PrEP (Coverage in days required: 154/180 (per six months))
Measured: Baseline through 36 months
HIV risk assessment PrEP ineligibility
Number of participants who undergo HIV risk assessment
Measured: Baseline through 36 months
PrEP eligibility
Number of participants identified as PrEP eligible
Measured: Baseline through 36 months
PrEP ineligibility
Number of participants identified as PrEP ineligible
Measured: Baseline through 36 months
PrEP offered
Number of participants offered PrEP
Measured: Baseline through 36 months
PrEP navigation
Number of participants receiving PrEP navigation services
Measured: Baseliend through 36 months
PrEP Education
Number of participants receiving PrEP education
Measured: Baseline through 36 months
Eligibility for PrEP Education
Number of participants who meet the following criteria: Age >18, do not have HIV, are attending an appointment where PrEP could be prescribed
Measured: Baseline through 36 months
Provider feedback
Number of CHC providers receiving feedback regarding their PrEP prescription rates
Measured: Baseline through 36 months
Change in provider knowledge and attitudes about PrEP
Average change in score between baseline and post intervention quiz on provider knowledge and attitudes about PrEP
Measured: Baseline through 36 months
Change in patient knowledge and attitudes about PrEP
Average change in score between baseline and post intervention quiz on patient knowledge and attitudes about PrEP
Measured: Post-intervention, month 37
Provider training
Number of providers who complete online training
Measured: Post-intervention, month 37
Providers who educate patients about PrEP
Number of providers who offer PrEP education to participants
Measured: Baseline through 36 months
Provider prescription of PrEP
Number of providers who prescribe PrEP to participants
Measured: Baseline through 36 months
Acceptability for providers
Average score among providers of the Acceptability of Intervention Measure tool (AIM)
Measured: Post-intervention, month 37
Acceptability for patients
Average score among patients of the Acceptability of Intervention Measure tool (AIM)
Measured: Post-intervention, month 37
Appropriateness
Average score among providers of the Intervention Appropriateness Measure tool (IAM)
Measured: Post-intervention, month 37
Appropriateness
Average score among patients Intervention Appropriateness Measure tool (IAM)
Measured: Post-intervention, month 37
Maintenance
Average score among providers of the Program Sustainability Assessment Tool (PSAT)
Measured: Post-intervention, month 37
Feasibility of intervention
Average score among providers on the Feasibility of Intervention Measure tool (FIM)
Measured: Post-intervention, month 37
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Nov 2022
- Study start10 Aug 2023
- Primary completion30 Apr 2026
- Study completion30 Apr 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for PrEP UptakeStudies of the same condition, open and under way.
- More trials run by University of ChicagoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This study will use a cluster randomized, cross-sectional stepped wedge study with 12 clusters (8 CHCs from the South and 4 CHCs from the Midwest) to evaluate the effect of the intervention package as compared to the control condition (usual care) on the proportion of PrEP prescriptions among eligible participants. Cross-sectional data from participants who are eligible for PrEP will be collected at 6 different calendar intervals of 6 months ("steps"). Although all clusters will begin the study in the control condition (usual care), beginning in step 3 at each six-month interval three randomly chosen CHCs (containing a mix of Southern and Midwestern CHCs) will switch from the control condition to the intervention condition. Beginning at step 2, the step prior to 3 CHCs switching from control to intervention condition will be spent in a six-month transition period. This design will allow for data collection at all CHCs to contain observations from both intervention and control periods.
- Masking
- None (open label)
- Enrolment
- 724 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Chicago
- Sponsor type
- University, hospital or other
- Collaborators
- AllianceChicago, Howard Brown Health Center, Ann & Robert H Lurie Children's Hospital of Chicago, Northwestern University, Rush University
- Responsible party
- Sponsor
- Investigators
- Jessica Ridgway, MD, MS, Principal investigator, University of Chicago
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05626452
- Sponsor's protocol ID
- IRB21-0971
- Acronym
- POWER Up
- Status last verified
- May 2026
- First submitted
- 15 Nov 2022
- Last updated
- 27 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Devlin SA, Ridgway JP, Dawdani A, Enaholo OE, Liegeon G, Kasal N, Pyra M, Hirschhorn LR, Simon J, Haider S, Ducheny K, Johnson AK. Adapting Provider Training and Pre-Exposure Prophylaxis Advertising to Increase Pre-Exposure Prophylaxis Awareness and Uptake Among Black Cisgender Women. AIDS Patient Care STDS. 2023 Dec;37(12):574-582. doi: 10.1089/apc.2023.0188. Epub 2023 Nov 21.
PubMed 38011350
Study at a glance
From the registry record, last updated by the sponsor on 27 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Implementation and Dissemination of Evidence-Based Interventions to Improve PrEP Care Continuum Outcomes Among Women in Community Health Clinics in the Southern U.S.
- ClinicalTrials.gov ID
- NCT05626452
- Acronym / sponsor ID
- POWER Up / IRB21-0971
- Conditions
- PrEP Uptake
- Keywords
- Pre-exposure prophylaxis, Stepped-wedge randomized trial
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 724 participants (actual)
- Lead sponsor
- University of ChicagoUniversity, hospital or other
- Collaborators
- AllianceChicago, Howard Brown Health Center, Ann & Robert H Lurie Children's Hospital of Chicago, Northwestern University, Rush University
- Study start
- 10 Aug 2023 (actual)
- Primary completion
- 30 Apr 2026 (actual)
- Study completion
- 30 Apr 2026 (actual)
- First posted
- 23 Nov 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Black women experience one of the highest incidences of HIV among all subpopulations in the United States, but pre-exposure prophylaxis (PrEP) use among Black cisgender women is very limited. The investigators will implement four strategies (provider training, patient education, EMR optimization, and PrEP navigation) at 12 community health clinics in the Midwest and South. The investigators predict that PrEP use and other related outcomes will improve for participants after the intervention period.
Detailed description
Research Design After the investigators have adapted the POWER-Up strategies for use in the new setting, the investigators will conduct a hybrid type II trial within the framework of a cluster randomized, cross-sectional stepped wedge study. The investigators will use the RE-AIM framework for evaluation. The investigators will utilize a cluster randomized, cross-sectional stepped wedge trial, including sites in the South and the Midwest. This study design will allow us to roll out the intervention across diverse geographic areas and assess the change in clinical and implementation outcomes from the pre-intervention (control) and the post intervention (intervention) periods. The cluster, or unit of analysis, is each CHC, N=12 (8 in the South, 4 in the Midwest). In a stepped wedge study, each cluster contributes both time and observations to the control condition (usual care) and the intervention condition (strategies to increase PrEP use). Every cluster switches from the control to the intervention at regular time intervals ("steps"), but at different points in calendar time. More than one cluster may start the intervention at a step, but the step at which a cluster switches from control to intervention is randomized. The design is cross-sectional as outcomes are obtained from the subset of patients seen during each time period at each clinic rather than following individually recruited patients over time. This use of clinics under both intervention and control conditions improves precision when intra-cluster correlation is high, which is likely among the CHCs the investigators have chosen.
In our stepped wedge design, each step is 6 months long, and there are 4 waves of intervention implementation (three sites begin the intervention at the same step, a mix from the South and the Midwest, N=12). Three CHC sites will be randomized to each step occurring at 6-month intervals. Each cluster also undergoes a 6-month transition period when the individual clinics will prepare to implement the intervention package.
Although the investigators hypothesize that the effect of this intervention will increase PrEP uptake among participants, the investigators powered this study to ensure that the investigators could detect a range of intervention effectiveness. The investigators used the R statistical package swCRTdesign V3.1 to verify that a sample of 50 participants at 6 different times ("steps") each lasting 6 months, at the 12 CHC sites ("clusters") provides adequate power (>80%) to detect a change from a baseline of 1% of eligible participants receiving prescriptions for PrEP to 2% with an ICC of 0.2 and a CAC of 0.80.60. This minimum sample size per time interval is one that can easily be met by all of the clinics used as sites in this study (100 eligible participants per calendar year).
A key element of the research infrastructure will be AllianceChicago's uniform EMR system, which is distinguished by the integration of evidence-based practice recommendations into the end user interface to provide clinical decision support at the point of care. AllianceChicago's information technology (IT) team will create a study specific fields to measure study outcomes. The IT team will build custom reports in their data warehouse to access and validate in real-time. Reports will be built to pull data (ICD, CPT/HCPCS, and RXNORM codes, laboratory results, demographic characteristics) from the medical record and billing claims, and will be used to determine implementation success for the RE-AIM outcomes of effectiveness and maintenance. The investigators will utilize the Health Catalyst Tool which already has reports built to monitor PrEP care continuum outcomes. Additional reports will be built to monitor: 1) Participants who receive HIV risk assessment 2) participants who receive PrEP education; 3) participants who receive PrEP navigation; 4) PrEP prescriptions among eligible participants.
Implementation Patient education: CHC staff will perform HIV risk assessment for participants who present at the CHCs for care. HIV risk assessment will consist of asking questions regarding PrEP indications adapted from the USHS guidelines for PrEP (e.g., sexual partners, recent STIs, condom use, drug use, etc). For participants who meet criteria of "PrEP eligibility," patient education regarding PrEP will be provided. Patient education occurs at each clinic visit.
Provider training: Providers will complete 3 sessions of 1-hour virtual trainings regarding PrEP (providing patient education, identifying PrEP-eligible participants, offering PrEP, etc.). CHCs will provide protected time for providers to complete the trainings. Trainings will be virtual but also interactive, including the opportunities for providers to use electronic avatars to practice difficult conversations with virtual participants. Monthly audit and feedback will be provided post-training to measure and support sustained behavior change. The investigators will integrate PrEP outcomes reports into the overall quality metric reporting for each clinic. Every month the medical director of each clinic reviews quality metrics for the clinical site. The medical director reports the metrics during monthly clinic meetings and steps are taken to address any metrics that fall short of the expected benchmark. Data on clinic staff's use of PrEP clinical decision support tools and PrEP care continuum outcomes will be incorporated into standard monthly quality report. During monthly site check-ins, the investigators will review this data with the medical director and clinical champions.
EMR optimization: AllianceChicago will incorporate PrEP clinical decision support, including PrEP indication documentation, PrEP order set, and electronic notifications of PrEP-eligible participants into the CHC's EMR and provide weekly reports of PrEP care continuum outcomes for the CHC to review and act upon.
PrEP navigation: The investigators will work with the CHCs to engage staff in the adapted PrEP support roles using manualized procedures and training. PrEP navigators will meet with participants 2-3 times initially to support PrEP uptake, and will check in with patients monthly thereafter (appointment, refill reminders will be based on participants' own schedules).
Monitoring and Process Evaluation with Feedback: The investigators will track the implementation process and provide feedback and support to the CHC for challenges in implementing the strategies, as well as ongoing feedback on interim outcomes including number of participants who underwent HIV risk assessment, the number who discussed PrEP with a provider, proportion initiating PrEP, and results of provider training. Results will be discussed between the research team and each CHC to understand barriers and identify and document adaptations needed using Stirman's FRAME methodology. Broadly, the investigators will discuss and document (1) what and why the investigators adapted, (2) goals of the adaptation, (3) who was involved in the adaptation process, (4) when the investigators adapted, (5) forms of adaptation, and (6) measurement and evaluation.
Evaluation: Utilizing the RE-AIM framework, the investigators will evaluate the success of the implementation strategies. The investigators will gather feedback from CHC providers, staff, and participants using mixed methods with both quantitative surveys and qualitative interviews. For evaluation of the provider training, The investigators will use the Kirkpatrick four-level training evaluation model. The investigators will use provider-level quantitative surveys to assess the four-levels of training: satisfaction and perceived value (Level 1); knowledge and self-efficacy (Level 2); application of knowledge (Level 3; i.e., number of participants offered PrEP); and effectiveness (Level 4; i.e., the increase in proportion of participants on PrEP). Data regarding number of participants who had PrEP education, discussions, and who initiated and persisted on PrEP will be collected from the EMR with electronic reports developed by AllianceChicago. To assess provider and CHC staff feedback about the implementation strategies, the investigators will use surveys to assess the following measures: Acceptability of Intervention Measure (AIM)), appropriateness (Intervention Appropriateness Measure (IAM)), and feasibility (Feasibility of Intervention Measure (FIM)). In addition, the investigators will recruit 400 participants to complete surveys regarding acceptability (AIM) of the POWER Up strategies.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- This study will use a cluster randomized, cross-sectional stepped wedge study with 12 clusters (8 CHCs from the South and 4 CHCs from the Midwest) to evaluate the effect of the intervention package as compared to the control condition (usual care) on the proportion of PrEP prescriptions among eligible participants. Cross-sectional data from participants who are eligible for PrEP will be collected at 6 different calendar intervals of 6 months ("steps"). Although all clusters will begin the study in the control condition (usual care), beginning in step 3 at each six-month interval three randomly chosen CHCs (containing a mix of Southern and Midwestern CHCs) will switch from the control condition to the intervention condition. Beginning at step 2, the step prior to 3 CHCs switching from control to intervention condition will be spent in a six-month transition period. This design will allow for data collection at all CHCs to contain observations from both intervention and control periods.
| Arm | Type | Receives |
|---|---|---|
| Usual Care | No intervention | –The current mechanisms used at each healthcare site to assess HIV risk/ take a sexual history, assess PrEP eligibility, identify PrEP ineligibility for otherwise PrEP eligible patients, provide PrEP education, offer PrEP, provide PrEP navigation, measure PrEP uptake, and measure PrEP persistence/retention. |
| Intervention | Experimental | Behavioral: PrEP Education, Behavioral: Provider training, Other: EMR Optimization, Other: PrEP Navigation, Other: Provider Audit and FeedbackImplementation of 1) Patient Education, 2) Provider PrEP training, 3) EMR optimization, and 4) PrEP navigation, and the effect of these intervention components on the ability of each site to assess HIV risk/take a sexual history, assess PrEP eligibility, identify PrEP ineligibility for otherwise PrEP-eligible patients, provide PrEP education, offer PrEP, provide PrEP navigation, measure PrEP uptake, and measure PrEP persistence/retention. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Age 18 years or older
- HIV-negative
Key exclusion criteria (2 listed)
- Younger than age 18 years
- HIV-positive
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PrEP EducationEducation for participants regarding PrEP | Behavioural | Intervention |
| Provider trainingTraining for medical providers at CHCs about how to identify participants eligible for PrEP, how to perform behavioral risk assessment and discussion of PrEP, and how to prescribe PrEP and monitor PrEP | Behavioural | Intervention |
| EMR OptimizationEMR modifications to enhance PrEP care continuum outcomes including HIV risk assessment, identification of participants eligible for PrEP, provision of PrEP education, clinical decision support tools for prescription of PrEP, and tracking of PrEP care continuum outcomes using an electronic population health management tool | Other | Intervention |
| PrEP NavigationUse of CHC staff members to assist participants with obtaining PrEP and attending PrEP care appointments | Other | Intervention |
| Provider Audit and FeedbackAudit of provider rates of PrEP prescription and persistence among participants and regular provision of feedback to providers with their performance on these PrEP measures | Other | Intervention |
Primary outcome
PrEP uptake
Time frame: Baseline through 36 months
Number of participants initiating PrEP
21 secondary outcomes
PrEP persistence consecutive months
Time frame: Baseline through 36 months
PrEP persistence amount of coverage
Time frame: Baseline through 36 months
HIV risk assessment PrEP ineligibility
Time frame: Baseline through 36 months
PrEP eligibility
Time frame: Baseline through 36 months
PrEP ineligibility
Time frame: Baseline through 36 months
PrEP offered
Time frame: Baseline through 36 months
PrEP navigation
Time frame: Baseliend through 36 months
PrEP Education
Time frame: Baseline through 36 months
Eligibility for PrEP Education
Time frame: Baseline through 36 months
Provider feedback
Time frame: Baseline through 36 months
Change in provider knowledge and attitudes about PrEP
Time frame: Baseline through 36 months
Change in patient knowledge and attitudes about PrEP
Time frame: Post-intervention, month 37
Provider training
Time frame: Post-intervention, month 37
Providers who educate patients about PrEP
Time frame: Baseline through 36 months
Provider prescription of PrEP
Time frame: Baseline through 36 months
Acceptability for providers
Time frame: Post-intervention, month 37
Acceptability for patients
Time frame: Post-intervention, month 37
Appropriateness
Time frame: Post-intervention, month 37
Appropriateness
Time frame: Post-intervention, month 37
Maintenance
Time frame: Post-intervention, month 37
Feasibility of intervention
Time frame: Post-intervention, month 37
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 May 2026.
- Derived from this study: PubMed 38011350Devlin SA, Ridgway JP, Dawdani A, Enaholo OE, Liegeon G, Kasal N, Pyra M, Hirschhorn LR, Simon J, Haider S, Ducheny K, Johnson AK. Adapting Provider Training and Pre-Exposure Prophylaxis Advertising to Increase Pre-Exposure Prophylaxis Awareness and Uptake Among Black Cisgender Women. AIDS Patient Care STDS. 2023 Dec;37(12):574-582. doi: 10.1089/apc.2023.0188. Epub 2023 Nov 21.
- Individual participant dataSharing planned: No
Related trials for PrEP Uptake
Not yet recruiting
Adapting the ESTEEM Intervention to Improve Mental Health and PrEP Uptake Among Men at Risk of HIV
PrEP Use
RecruitingPhase 4
Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP
HIV Prevention, HIV Pre-exposure Prophylaxis
Active, not recruiting
Optimizing PrEP Uptake and Adherence Among Male Sex Workers
Prevention
Active, not recruiting
Pre-exposure Prophylaxis (PrEP) for Health
Substance Dependence, HIV (Human Immunodeficiency Virus)
Recruiting
Trans STAIR: Implementing an Evidence Based Trauma Treatment With Community Led PrEP Navigation
PrEP Uptake Experiences, PrEP Adherence Experiences
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jessica Ridgway, MD, MS principal investigator
University of Chicago
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing PrEP Education, Provider training and EMR Optimization in people with PrEP Uptake, run by University of Chicago at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
PrEP uptake (time frame: Baseline through 36 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05626452, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 May 2026.